期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Off-label use of targeted therapies in oncology
1
作者 Dominique Levêque 《World Journal of Clinical Oncology》 2016年第2期253-257,共5页
Off-label use is defined by the prescription of a marketed drug outside the conditions described in the summary of product characteristics.In oncology,off-label prescribing of targeted therapies may occur in patients ... Off-label use is defined by the prescription of a marketed drug outside the conditions described in the summary of product characteristics.In oncology,off-label prescribing of targeted therapies may occur in patients with other tumor types expressing the same target.Agents associated to phenotypic approaches such as therapies against the tumoral vasculature(anti-angiogenic drugs) and new immunotherapies(checkpoint inhibitors) also carry the potential of alternative indications or combinations.Off-label use of targeted therapies is little documented and appears to be in the same range than that regarding older drugs with wide variations among agents.When compared with older agents,off-label use of targeted therapies is probably more rational through tumoral genotyping but is faced with a limited clinical support,reimbursement challenges related to the very high pricing and the cost of genotyping or molecular profiling,when applicable. 展开更多
关键词 Targeted therapy Monoclonal antibody Off-label anticancer drug use REIMBURSEMENT Enzyme inhibitor
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部